The Biofield Energy Treatment and its Effect on the Relative Oral Bioavailability of Lovastatin Hydroxy Acid in Rats after a Single Oral Dose of Lovastatin

Abstract

Lovastatin is a lipid-lowering drug used to reduce the risk of cardiovascular disease. Lovastatin shows poor oral bioavailability (<5%) because of its low water solubility and short half-life. Therefore, the present study was performed to determine the effects of the Trivedi Effect ® - Consciousness Energy Treatment (Blessing) on lovastatin and rats through the measurement of plasma lovastatin hydroxy acid concentrations after the oral administration of lovastatin in rats. The test item, lovastatin was divided into two parts. One part was denoted as the control, while the other part was defined as the Biofield Energy Treated sample, which received the Biofield Energy Treatment for about 3 minutes by renowned Biofield Energy Healer, Dahryn Trivedi. Additionally, one group of animals also received Biofield Energy Treatment under similar conditions. The Biofield Energy Healer who was located in the USA, while the test samples and animals were located in the research laboratory in India. Lovastatin oral formulations were administrated by oral gavage at a dose of 50 mg/kg in groups viz . G1 (untreated lovastatin), G2 (Biofield Treated lovastatin), and G3 (Biofield Treated animals received untreated lovastatin) group. The majority of lovastatin was rapidly converted to its metabolite, i.e. , lovastatin hydroxy acid following the oral administration. The pharmacokinetic parameter, the C max of lovastatin hydroxy acid was significantly altered by 155.76% and -24.82% in G2 and G3, respectively compared to G1. The T max of lovastatin hydroxy acid was significantly increased by 254.55% in G2 and 51.52% in G3 compared to G1. The mean residence time of lovastatin hydroxy acid was also altered in G2 (-30.46%) and G3 (3.96%), as compared to the G1. The relative oral bioavailability (Fr) of lovastatin was significantly increased by 281.87% in the group G2 and 15.71% in the group G3 compared to the G1. These data suggest that the Biofield Energy Treatment could be considered as an innovative strategy that opens new avenues to improve the bioavailability of nutraceuticals/pharmaceuticals and can also modulate the therapeutic performance of orally active molecules. The Biofield Energy Treated lovastatin could be beneficial for the treatment of cardiovascular disease, which includes heart attack, stroke, atherosclerosis, coronary revascularization, coronary death, myocardial infarction, unstable angina, peripheral artery disease, abdominal aortic aneurysm, chronic kidney disease, etc.